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Original Studies
Background: the duration of protection after hepatitis B vaccination in 
early infancy is unclear and may be related to vaccination schedule, dosage, 
vaccine type and population characteristics. Factors potentially influencing 
waning immunity were assessed.
Methods: a systematic review was performed. the main outcomes were 
prevalence of anti-hepatits B antibodies ≥ 10 miu/ml after primary or 
booster vaccination. Factors potentially influencing protection were assessed 
in an adjusted random-effects meta-analysis model by age for both out-
comes. results of both meta-analyses were combined in a prognostic model.
Results: Forty-six studies reporting on the anti-hepatits B antibodies ≥ 
10 miu/ml 5 to 20 years after primary immunization and 29 on booster 
response were identified. the adjusted meta-analyses identified maternal 
carrier status (odds ratio [Or]: 2.37 [1.11; 5.08]), lower vaccine dosage than 
presently recommended (Or: 0.14 [0.06; 0.30]) and gap time between last 
and preceding dose of the primary vaccine series (Or: 0.44 [0.22; 0.86]) 
as determinants for persistence of anti-hepatits B antibodies ≥ 10. a lower 
vaccine dosage was also associated with failure to respond to booster (Or: 
0.20 [0.10; 0.38]). the prognostic model predicted long-term protection of 
90% [77%; 100%] at the age of 17 years for offspring of noncarrier mothers 
vaccinated with a presently recommended dose and vaccination schedule.
Conclusions: Based on meta-analyses, predictors of waning immunity 
after hepatitis B vaccination in infancy could be identified. a prognostic 
model for long-term protection after hepatitis B vaccination in infancy 
was developed.
Key Words: hepatitis B, infant vaccination, booster, long-term protection, 
determinants of protection
(Pediatr Infect Dis J 2013;32: 307–313)
Although hepatitis B vaccination is highly effective, vaccina-tion failures leading to acute1–5 and sometimes chronic infec-
tion5–8 have been observed. although infections occurring within 
a short time interval after vaccination are likely to reflect primary 
vaccination failure1,4 due to nonresponse, those occurring after 
decades are likely to reflect secondary vaccination failure due to 
waning immunity. anti-hepatits B antibodies [anti-HBs] ≥ 10 miu/
ml either after primary vaccination or as response to booster if 
the antibody concentrations have fallen below are widely accepted 
marker of protection after hepatitis B vaccination.9–11 immunity 
against hepatitis B gives protection against infection and protec-
tion against disease.12–14 Protection against infection is based on 
the presence of anti-HBs ≥ 10 miu/ml. after vaccination against 
hepatitis B, the proportion of individuals with anti-HBs ≥10 miu/
ml is highly dependent on the time elapsed since primary vacci-
nation. individuals whose anti-HBs concentrations dropped below 
a level of 10 miu/ml are not protected any more against infec-
tion with hepatitis B virus. However, they are not at risk of hepatic 
disease as long as they have hepatitis B surface antigen (HBsag)-
specific immune memory. Memory persists beyond the time during 
which anti-HBs is present and protects against clinically relevant 
disease.12–14 in case of hepatitis B virus exposure, memory rapidly 
leads to a vigorous anamnestic response, which prevents acute dis-
ease, prolonged viremia and chronic infection. specific memory 
after hepatitis B vaccination is demonstrated by an anamnestic anti-
HBs response after vaccination with an additional vaccine dose.15 
this dose acts as a booster leading to a rapid increase in anti-HBs 
in most of individuals who had successfully responded to the initial 
series of vaccinations. Persistence of immune memory is appeared 
to be related also to the time after primary vaccination.16
in most countries with universal hepatitis B vaccination, 
vaccine is given in infancy.17 We, therefore, focused our study on 
the duration of protection after infant immunization. although 
quite a number of studies exist dealing with the persistence of 
anti-HBs after primary immunization or analyzing the response to 
a booster dose after anti-HBs has dropped below 10 miu/ml18–26, 
there is no systematic investigation assessing determinants for wan-
ing immunity.
Persistence of anti-HBs ≥ 10 miu/ml and response to 
booster vaccination19,21,23 may be related to vaccine dosage,27–30 
beginning of the primary vaccine regime (at birth or later in 
infancy),22,28,29,31–33 timing of the last vaccination of the primary 
series (ie, the gap time between last and preceding dose),4,33 num-
bers of vaccine doses given as primary vaccine series4 and use of 
plasma-derived or recombinant vaccines.4,8,11,19,28,31–37 Finally, both 
parameters may also be influenced by the prevalence of hepatitis 
B infection in the population and the HBsag carrier status of the 
mothers in the country.6,7,11,21,22,28–33,35,37,38 all these studies, however, 
are difficult to compare because results are influenced by a mixture 
of causes as well as by different follow-up periods.
Based on a systematic review on studies providing 
information on the duration of anti-HBs ≥ 10 miu/ml persistence 
after hepatitis B vaccination started within the first 6 months of life 
and on the response to booster vaccination in individuals with anti-
HBs concentrations <10 miu/ml, we performed meta-analyses to 
identify relevant factors for duration of protection. a prognostic 
model to predict the proportion of vaccinated individuals likely to 
be protected is presented.
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METHODS
Case Definitions
Proportion of children/adolescents with anti-HBs titers ≥ 
10 miu/ml; proportion of children/adolescents with a response 
to booster vaccination (anti-HBs titers ≥ 10 miu/ml among those 
with prior anti-HBs titers < 10 miu/ml).
Description of Search Strategy
studies were identified through searches of the 3 databases 
Medline, eMBase and Cochrane library of Clinical trials and 
additionally by hand search in relevant publications in september 
2011. any study published in english was eligible if reporting data 
on children who were vaccinated with a hepatitis B vaccine and 
had their first dose before an age of 6 months. the search syntax 
was: (Hepatitis B [all Fields]) and (Vaccine Or vaccination Or 
immunization [all Fields]) and (immunogenicity Or immunity 
Or antibody Or waning [all Fields]) and (infants Or children 
Or adolescents Or toddler Or newborn Or birth Or cohort [all 
Fields]).
Data Extraction
two independent reviewers read the titles and abstracts of all 
retrieved articles according to the inclusion criteria. disagreement 
regarding the relevance of specific articles prompted second review 
of the titles/abstracts and was resolved by consensus.
data collected were name of authors, name of journal, coun-
try of the study, age of the subjects at follow-up, HBsag carrier 
status of mothers, response to primary immunization, vaccination 
schedule, types of vaccines used, dosage, number of children tested 
and number and percentage of children with detectable anti-HBs, 
type and dosage of booster dose if applicable. in case of missing 
data, the corresponding study authors were contacted.
any observational studies (cross-sectional or cohort stud-
ies) reporting proportions of anti-HBs titers ≥ 10 miu/ml with or 
without information on response to a booster dose in subjects who 
had been vaccinated against hepatitis B in infancy were considered. 
We excluded all studies if the 1st vaccination was given later than 
6 months of age, if the follow-up was shorter than 5 years, if not 
all children were vaccinated in the reported (sub-) populations or 
if the age range within reported age groups was ≥ 5 years. Further-
more studies were not included if a booster dose was given between 
completed infant vaccination schedule and age at follow-up or if 
the vaccine was not given by intramuscular injection. additionally, 
we did not include studies with inconsistent data or not reporting 
original data (review or editorial letter).
determinants considered to assess the decrease of anti-HBs ≥ 
10 miu/ml were responder status (anti-HBs antibody titers ≥ 10 
miu/ml after primary vaccination), maternal carrier status (HBsag 
positive versus negative), prevalence of chronic hepatitis B infec-
tion (as outlined in [39]) in the study country, vaccine type (recom-
binant or plasma derived), timing of first vaccination and vaccina-
tion schedules (number of vaccine doses; gap time between last 
and preceding dose of hepatitis vaccination <6 months, 6 to 8 or >  
8 months). the booster response was defined by antibody titers ≥  
10 miu/ml 1 week after the booster administration or later.
Statistical Analyses
We calculated multivariate random-effects models to control 
for study-specific uncertainties on a binary outcome (proportions of 
individuals with anti-HBs ≥ or < 10 miu/ml) applying generalized 
mixed effects models with a random intercept allowing for adjust-
ment for potential protective or risk factors as previously applied 
in meta-analyses of observational and registry bases studies.40,41 
Variables supposed to be associated with protection by hepatitis B 
vaccination in univariate analyses (P < 0.05) were included in the 
multivariate random-effects models by backward selection. apply-
ing this approach allows to include all studies irrespective of the 
vaccinees’ age at follow-up and to adjust for confounding by a 
number of different study characteristics.
the logarithmized random-effects models were calculated 
with the underlying formula p = exp(η)/(1 + exp[η]). For model 
estimation, the independent variable age was centered (subtracting 
the mean age from age of each case). For all analyses a significance 
level of 0.05 was applied. the final models were selected by p-level 
based backward selection.
in order to identify the population of individuals protected by 
either anti-HBs ≥ 10 miu/ml or response to booster, we combined 
the results of the respective meta-analyses. the proportion of indi-




with anti-HBs titers ≥ 10 miu/ml + propotionwith anti-HBs titers < 10 miu/ml × 
proportion
with response to booster
.
sensitivity analyses were conducted for both meta-analyses 
based on the methodological quality of the included studies (vac-
cination status of population, age at assessment, losses to follow-
up) according to the gate statement (graphic appraisal tool for 
epidemiological studies).42 Calculations were performed with r 
2.13.0 by using glmer (package lme4, Vienna, austria).
RESULTS
an overview of the literature search strategy is depicted in 
Figure, supplemental digital Content 1, http://links.lww.com/inF/
B407. table, supplemental digital Content 2, http://links.lww.com/
inF/B408, summarizes all studies reporting anti-HBs ≥ 10 miu/
ml in 5 to 20 years old vaccinees. Because several studies reported 
on >1 subpopulation, all relevant subpopulations are listed sepa-
rately. Measurement of the same individuals at different time points 
reported in 12 subpopulations was given a supplemental identifier 
in the random effects model. the analysis was confined to studies 
with full information on potential confounders leaving 55 subpopu-
lations on 28,329 individuals, 15,944 (56.3%) with anti-HBs ≥ 10 
miu/ml at the respective time of measurement.
Figure 1 shows the proportions of individuals with 
anti-HBs ≥ 10 miu/ml by size of study population and age of the 
individuals which decrease by age. although most big studies were 
close to the estimated waning curve, the smaller studies scattered 
more widely and equally above and below.
in 13 subpopulations1,2,28,29,32,33 on 982 individuals aged 
between 5 and 17.7 years reporting proportions of anti-HBs ≥ 10 
miu/ml were <25%. three characteristics were shared by most of 
these subpopulations: gap time between last and preceding dose 
of primary vaccination series <6 month, first dose of vaccine was 
given at birth and vaccination with a lower than the presently rec-
ommended dose.
subpopulations with proportions of anti-HBs ≥ 10 miu/
ml >90% until the age of 13 years or >60% thereafter had been 
vaccinated with a normal dose, with a gap time between last and 
preceding dose of primary vaccination >6 months and included 
offspring of carrier mothers. in 605 of them reported repetitive 
measurements in the same individuals at different time points.30
risk factors for the decrease in proportions of individuals 
with anti-HBs ≥ 10 miu/ml were assessed in univariate and multi-
variate analyses (table 1). We did not include the child’s responder 
status after the primary immunization in the analyses because 
responder status was only defined in 359 of 28,329 individuals. in 
univariate analyses, significant associations were observed with 
maternal carrier status, vaccine dosage, gap time between last 
and preceding dose of primary vaccination series <6 months and 
the number of vaccine doses. after mutual adjustment, only a gap 
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time <6 months and a lower vaccine dosage were related with lower 
proportions of anti-HBs ≥ 10 miu/ml. Maternal carrier status was 
associated with higher proportions of anti-HBs ≥ 10 miu/ml.
table, supplemental digital Content 3, http://links.lww.com/
inF/B409, summarizes included studies on response to booster. all 
relevant subpopulation are listed separately. as in the meta-analysis 
on vaccinees showing anti-HBs ≥ 10 miu/ml 5 to 20 years after 
infant vaccination, we only included studies with full information 
on potential predictors. thus, we analyzed 42 subpopulations with 
3,235 individuals of whom 2,663 (82.3 %) responded to the booster 
vaccination.
Figure 2 shows the subpopulations reporting booster 
response by age (5 to 17.7 years). the distribution of the boxes scat-
ters around the estimated waning curve with small studies equally 
distributed above and below. three studies reported particularly 
low response to booster (67%)22 in 5-year-old children, 52%32 in 
9-year-old children and 44% in 15-year-old children.1 in 2 of these 
studies,1,32 children had received a lower than the presently recom-
mended vaccine dose at vaccination in infancy. the third study22 
was based on 3 children only vaccinated with a normal vaccine 
dose.
in univariate analyses, response to booster vaccination in 
children with anti-HBs < 10 miu/ml was significantly associated to 
primary vaccination with a lower than the presently recommended 
dose and the number of doses at primary immunization. these 
variables were considered in the multivariate meta-analyses. in 
the adjusted final model—in addition to age—only the lower dose 
remained significantly associated with a lower response to the 
booster dose (table 2).
Prediction of our model for subpopulations to be protected 
at different ages by risk status was compared with a major european 
study reporting anti-HBs ≥ 10 miu/ml and response to booster.24 
the point estimated for protection rate in this study was 98% after 
10 years as compared with 97% (95% confidence interval: 92%; 
100%) estimated in the prognostic model. Modeled protection rates 
up to an age of 17 years for offspring of non-HBsag carrier moth-
ers for different scenarios are shown in table 3. among offspring 
of noncarrier mothers vaccinated with a recommended dose and a 




random effects model  for  children  vaccinated with hepati-
tis B vaccine in infancy. The boxes represent the size of the 
study population.
TABLE 1. Stratified and Adjusted Analyses of Determinants Potentially Influencing the Decrease of Anti-HBs ≥ 10 
mIU/mL 5 to 20 Years After the Primary Vaccination
Factors With a Potentially  
Influence Values N
Univariate (Stratified) Multivariate (Adjusted)
OR 95% CI OR 95% CI
Age at follow-up Metric variable 28329 0.83 [0.81; 0.85] 0.84 [0.82; 0.85]
Mothers HBsAg carrier status* Unspecified 21601 1.68 [0.71; 3.96] 1.33 [0.73; 2.40]
Positive 2142 4.14 [1.59; 10.75] 2.37 [1.11; 5.08]
Negative 4586 Ref Ref
Endemicity Endemic (intermediate and high) 24006 0.44 [0.19; 1.05] † †
Nonendemic (low) 4323 Ref † †
Vaccine type (infancy vaccination) Recombinant 12158 0.50 [0.23; 1.09] † †
Plasma derived 16171 Ref † †
Dosage of infancy vaccination (com-
pared to present recommendation)
Normal/high 27308 Ref Ref
Lower dose 1021 0.06 [0.03; 0.15] 0.14 [0.06; 0.30]
Time point of first vaccine dose At birth 24331 Ref † †
Second month of life or later 3998 2.06 [0.77; 5.52] † †
Vaccination schedule of infancy  
vaccination
Gap time between last and  
preceding dose <6 mo
3867 0.27 [0.12; 0.59] 0.44 [0.22; 0.86]
Gap time between last and  
preceding dose between 6 and 8 mo
8176 Ref Ref
Gap time between last and  
preceding dose >8 mo
16286 1.91 [0.80; 4.59] 1.19 [0.54; 2.63]
Numbers of vaccine doses 3 doses 11719 Ref
4 doses 16610 3.79 [1.68; 8.55] 1.02 [0.32; 3.27]
Significant results were printed in bold.
*1423 of 2142 (66%) offspring of documented carrier mothers received immunoglobulin in conjunction with the first dose of hepatitis B vaccination.
†Not included in multivariate model (no significant influence after the univariate/stratified analyses).
OR indicates odds ratio; CI, confidence interval.
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gap time between last and preceding dose of 6–8 months, for exam-
ple, 92% (95% confidence interval: 0.82; 1.00) were likely to be 
protected after 15 years. the proportion of individual likely to be 
protected was slightly reduced by a shorter gap time and consider-
ably reduced if a lower than recommended dose had been given for 
primary vaccination.
Failure to report losses to follow-up and potentially flawed 
or insufficient documentation of the vaccination status were con-
sidered as potential sources of bias.42 excluding these studies 
accounted for only marginal changes of the effect estimates in the 
multivariate analyses (data not shown).
DISCUSSION
the proportion of individuals with anti-HBs ≥ 10 miu/ml 
decreased by age confirming what is well known since many years. 
Consistently lower proportions were observed in children vacci-
nated with a lower than presently recommended dose. a gap time 
between last and preceding dose of primary vaccination series of <6 
months was associated with a lower proportion of individuals with 
protective anti-HBs. significantly higher estimates in offspring of 
carrier mothers were observed. the response to booster similarly 
decreased by age. the decrease was accelerated by vaccination 
with a lower vaccine dose than presently recommended given at 
primary vaccination. We developed a prognostic model on long-
term protection after primary hepatitis B vaccination in infancy.
a negative impact of vaccination with lower than presently 
recommended vaccine doses seems to be biological plausible and 
has been reported,29,30,43 whereas a higher dosage was related to 
higher and longer lasting anti-HBs concentrations.27,29,30
in offspring of carrier mothers, the proportion of individuals 
with anti-HBs ≥ 10 miu/ml was more than twice as high com-
pared with noncarrier mothers, whereas maternal carrier status 
was not related to the booster response. natural boosting by close 
contact to the carrier mother during infancy is believed to be instru-
mental.7,11,21,22,29–32,35,37,38
the association between longer gap time between the last 
and preceding dose of primary vaccination has been discussed 
in several other studies.29,33,44–46 this may be explained by a more 
mature immune system in older infants31,33 and maturation of the 
immune memory during the longer interval between the last 2 
doses as shown for polio, hepatitis B and hepatitis a vaccine in 
children and adults.44–46
differences in the protective effect of plasma versus recom-
binant vaccines have been under debate for a while.4,8,11,19,28,34,35,37,47 
Comparison of plasma and recombinant vaccines needs to take 
account of age at follow-up time, vaccination schedules and dos-
age. in our analysis, we did account for these confounding factors 
and could not identify differences between plasma and recombi-
nant vaccines. Previously reported differences are therefore might 
reflect differences in setting, vaccination protocol and ages at fol-
low-up or chance.4,8,28
the endemic status of the country was neither associated 
with a difference in waning proportions of individuals with anti-
HBs ≥ 10 miu/ml nor with the booster response. some of the 
unexpected findings regarding, for example, the seemingly lower 
vaccine effects in intermediate endemic countries must be inter-
preted in context with the vaccination protocols in the reported 
studies and possibly use of measures to prevent reexposure such 
as safer injections, blood supply and availability of barrier methods 
would prevent reexposure also. so higher penetration of interven-
tions to secure these might reflect still high endemicity (for years to 
come), but low transmission. in several studies from intermediate 
endemic countries, alaska in particular, vaccination programs were 
performed with a lower than the presently recommended vaccina-
tion dose.28,29,32,33
some authors reported lower proportions of individuals with 
anti-HBs ≥ 10 miu/ml if the first vaccine dose had been given 
directly after birth,22,29,32 whereas Mele et al48 failed to confirm such 
an association. Our meta-analyses are in accordance with the obser-
vations by Mele at al. therefore, a first dose at birth does not appear 
to be related to lower proportions of individuals with anti-HBs ≥ 
10 miu/ml, supporting the use of vaccination schedules starting 
at birth in order to attain higher vaccination rates and timely vac-
cination.
in the adjusted analyses, the number of doses given at pri-
mary immunization was neither significantly associated to the per-
sistence of anti-HBs ≥ 10 miu/ml nor to response to booster. Pre-
vious reports on the associations to the beginning of immunization 
and the number of administered doses might reflect confounding, 
for example, by a gap time <6 months between the last and the 
preceding dose of the vaccination series.29,30,32
to our knowledge, this is the first systematic review and 
meta-analysis on the long-term impact of factors influencing the 
duration of protection and on the response to a booster dose in 
individuals vaccinated against hepatitis B in infancy.42,49 the 
sensitivity analyses did not identify aspects of study quality, which 
might be relevant for the analyses. since we could not assess 
publication bias in a funnel plot, because funnel plot assessment 
cannot take account of differences in follow-up time, which is 
a major determinant for waning immunity, we scrutinized the 
distribution of small studies around the overall estimate of the 
waning curve. absence of potential publication bias is suggested 
in Figures 1 and 2: at any given age, the individual studies scatter 
equally around the best estimate as indicated by the waning 
curves. scattering is evidently not related to the size of the boxes. 
Heterogeneity was considered in the random-effects model by the 
intercept for study population and the covariates.50 Current methods 
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for meta-analysis still leave a number of unresolved issues, such as 
the choice between fixed- and random-effects models, the choice of 
population distribution in a random-effects analysis, the treatment 
of small studies and extreme results, and incorporation of study-
specific covariates. these problems are all met in our systematic 
review. smith et al51 describe how likelihood-based or bayesian 
analyses can deal with these and other issues in a natural way. this 
technique is now well established and often used.52 a good model 
fit could be seen by variance reduction of the random effect in our 
analyses. the variance in the analysis of anti-HBs ≥ 10 miu/ml 
decreased from 2.33 in the empty model to 0.79 in the final model 
(adjusting for carrier status, vaccination dose and time gap between 
last and preceding dose) and in the analysis of the response to 
booster from 1.23 in the empty model to 0.34 in the final model 
(adjusting for vaccination dose). this means that a large part of the 
variation is explained by the predictors identified.
there is clear evidence from high-risk populations that the 
risk for breakthrough infections increases with time since vac-
cination.53 Peak anti-HBs titer correlate quite well with anti-HBs 
concentrations after 10 to 20 years, which are inversely corre-
lated to the frequency of seroconversion to anti-HBs indicating 
that protection against infection is a function of anti-HBs.9–11 
anti-HBs concentrations ≥ 10 miu/ml and booster response 
are widely used markers for protection against infection or dis-
ease.12,44,54 therefore, the proposed prognostic model, which 
allows for adjustment for risk and protective factors for waning 
immunity, is likely to reflect the increasing risk for infection after 
vaccination in infancy by age.
TABLE 2. Stratified and Adjusted Analyses of Determinants Potentially Influencing the Response to Booster 
Vaccination in Children With Anti-HBs < 10 mIU/mL 5 to 17.7 Years After the Primary Vaccination
Factors With a Potentially  
Influence Values n
Univariate Multivariate (Adjusted)
OR 95% CI OR 95% CI
Age at follow-up Metric variable 3235 0.83 [0.76; 0.91] 0.91 [0.85; 0.98]
Child’s responder status after primary 
vaccination
Yes 287 1.39 [0.61; 3.14] † †
Unspecified 2948 Ref † †
Mothers HBsAg carrier status* Unspecified 1776 1.04 [0.47; 2.30] † †
Positive 80 3.87 [0.89; 16.73] † †
Negative 1379 Ref † †
Endemicity Endemic (intermediate and high) 2037 0.49 [0.23; 1.06] † †
Nonendemic (low) 1198 Ref † †
Vaccine type (infancy vaccination) Recombinant 1655 0.99 [0.45; 2.18] † †
Plasma derived 1580 Ref † †
Dosage of infancy vaccination (compared 
with present recommendation)
Normal/high 2975 Ref Ref †
Lower dose 260 0.20 [0.10; 0.38] 0.20 [0.10; 0.38]
Time point of first vaccine dose At birth 2091 Ref † †
>1 mo of life 1144 1.69 [0.78; 3.69] † †
Vaccination schedule of infancy  
vaccination
Gap time between last and  
preceding dose <6 mo
574 0.52 [0.26; 1.06] † †
Gap time between last and  
preceding dose between 6 and 8 mo
1189 Ref † †
Gap time between last and  
preceding dose >8 mo
1472 1.34 [0.53; 3.38] † †
Numbers of vaccine doses at vaccination 
in infancy
3 doses 1766 Ref Ref
4 doses 1469 2.50 [1.04; 5.99] 0.79 [0.35; 1.81]
Vaccine type (booster vaccination) Recombinant 3232 10.45 [0.52; 208.97] † †
Plasma derived 3 Ref † †
Dosage of booster vaccination (compared 
with present recommendation)
Normal/high 2526 Ref † †
Lower dose 709 0.68 [0.32; 1.45] † †
Significant results were printed in bold.
*70 of 80 (88%) offspring of documented carrier mothers received immunoglobulin in conjunction with the first dose of hepatitis B vaccination.
†Not included in multivariate model (no significant influence in univariate/stratified analyses).
OR indicates odds ratio; CI, confidence interval.
TABLE 3. Proportions of Offspring of Noncarrier Mothers Likely to be Protected Against Hepatitis After Primary 
Vaccination in Infancy
Hepatitis B Vaccination in Infancy
Proportion of Individuals Protected After Vaccination by Age
At 5 yr (95% CI) At 10 yr (95% CI) At 15 yr (95% CI) At 17 yr (95% CI)
Estimation irrespective of dose and  
vaccination schedule
0.99 [0.97; 1.01] 0.95 [0.88; 1.02] 0.84 [0.65; 1.04] 0.77 [0.51; 1.03]
Dosage Vaccination Schedule At 5 yr (95% CI) At 10 yr (95% CI) At 15 yr (95% CI) At 17 yr (95% CI)
Adequate Gap time <6 0.98 [0.95; 1.01] 0.95 [0.89; 1.01] 0.90 [0.78; 1.02] 0.87 [0.72; 1.03]
Adequate Gap time 6–8 0.99 [0.97; 1.00] 0.97 [0.92; 1.01] 0.92 [0.82; 1.02] 0.90 [0.77; 1.02]
Lower Gap time <6 0.82 [0.74; 0.90] 0.71 [0.60; 0.83] 0.59 [0.46; 0.73] 0.54 [0.40; 0.68]
Lower Gap time 6–8 0.85 [0.71; 1.00] 0.74 [0.52; 0.96] 0.61 [0.33; 0.88] 0.55 [0.27; 0.84]
CI indicates confidence interval of the prediction.
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CONCLUSIONS
Based on these 2 meta-analyses, relevant factors influencing 
the duration of protection after hepatitis B vaccination in infancy 
could be identified. a prognostic model for long-term protection 
after hepatitis B vaccination in infancy was developed.
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